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Abstract
Background:  AVI-014 is an egg white-derived, recombinant, human granulocyte colony-
stimulating factor (G-CSF). This healthy volunteer study is the first human investigation of AVI-014.
Methods: 24 male and female subjects received a single subcutaneous injection of AVI-014 at 4 or
8 mcg/kg. 16 control subjects received 4 or 8 mcg/kg of filgrastim (Neupogen, Amgen) in a partially
blinded, parallel fashion.
Results: The Geometric Mean Ratio (GMR) (90% CI) of 4 mcg/kg AVI-014/filgrastim AUC(0–72
hr) was 1.00 (0.76, 1.31) and Cmax was 0.86 (0.66, 1.13). At the 8 mcg/kg dose, the AUC(0–72)
GMR was 0.89 (0.69, 1.14) and Cmax was 0.76 (0.58, 0.98). A priori pharmacokinetic
bioequivalence was defined as the 90% CI of the GMR bounded by 0.8–1.25. Both the white blood
cell and absolute neutrophil count area under the % increase curve AUC(0–9 days) and Cmax
(maximal % increase from baseline)GMR at 4 and 8 mcg/kg fell within the 0.5–2.0 a priori bound
set for pharmacodynamic bioequivalence. The CD 34+ % increase curve AUC(0–9 days) and Cmax
GMR for both doses was ~1, but 90% confidence intervals were large due to inherent variance, and
this measure did not meet pharmacodynamic bioequivalence. AVI-014 demonstrated a side effect
profile similar to that of filgrastim.
Conclusion: AVI-014 has safety, pharmacokinetic, and pharmacodynamic properties comparable
to filgrastim at an equal dose in healthy volunteers. These findings support further investigation in
AVI-014.
Background
Granulocyte colony stimulating factor (G-CSF) is a
cytokine produced by monocytes, macrophages, endothe-
lial cells, and fibroblasts. Human G-CSF consists of 174
amino acids with an approximate molecular weight of 20
kDa. The native protein is O-glycosylated on threonine
133. G-CSF plays a critical role in the modulation of neu-
trophil biology. It is required to maintain adequate basal
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neutrophil count, as well as generation of an appropriate
neutrophilia in response to infectious stimuli [1]. Primary
effects of G-CSF on neutrophils include an increase in cell
division and a decrease in marrow transit time; the net
effects of both functions being to increase the total neu-
trophils [2]. Other effects of G-CSF on neutrophils include
attraction and localization to sites of infection, increase in
phagocytosis and a decrease in apoptosis.
Filgrastim is a recombinant human granulocyte colony
stimulating factor (rhG-CSF) which was developed in the
mid-1980's and FDA-approved for use in chemotherapy
induced neutropenia in 1991 [3]. Filgrastim is a non-gly-
cosylated protein produced in E. coli bacteria transfected
with rhG-CSF cDNA. Two other products approved in sev-
eral countries include lenograstim, which is derived from
mammalian cells and is glycosylated, and nartograstim
which is non-glycosylated and has 5 different amino acids
at the N-terminal region as compared with the natural
human G-CSF. All the three versions of rhG-CSF have
been successfully used to treat chemotherapy-induced or
other forms of neutropenia for over a decade and appear
to have similar efficacy [4]. Specific indications for rhG-
CSF include primary prophylaxis in high-risk patients
receiving chemotherapy, treatment of chemotherapy-
induced neutropenic fever, and use in hematopoietic stem
cell transplantation [5]. In 2002, a pegylated filgrastim
with extended duration of action relative to the naked fil-
grastim was approved by the FDA.
AVI-014 is a transgenic glycosylated rhG-CSF produced by
purification from egg whites of hens transfected with hG-
CSF cDNA. The threonine residue at position 133 is glyc-
osylated and the protein has a molecular weight of
approximately 20 kD. Matrix assisted laser desorption/
ionization time-of-flight (MALDI-TOF) analysis shows
this species has the same polypeptide sequence as the nat-
ural human G-CSF. AVI-014 shows immunoreactivity
with rhG-CSF-specific antibodies in a Western blot assay
and bioactivity in a cell proliferation assay. Biologic activ-
ity (~1.5 × 108 IU/mg) in NFS-60 cells shows equipotency
to filgrastim.
The goal of this first-in-human study was to characterize
the safety, tolerability, pharmacokinetics, and pharmaco-
dynamics of AVI-014 in healthy human volunteers upon
subcutaneous administration of a single dose, and to
compare it to the existing commercially available rhG-CSF
product, filgrastim.
Methods
Subjects
Forty healthy volunteers were enrolled in this study. Writ-
ten informed consent was obtained from each subject
prior to the initiation of any study procedures. The study
protocol conformed to the ethical guidelines of the Decla-
ration of Helsinki as reflected in approval by the Institu-
tional Review Board of Thomas Jefferson University.
Subjects were considered to be in good health on the basis
of medical history, physical examination, laboratory val-
ues, and electrocardiograms (ECG). No subject used pre-
scription or over-the-counter medications, with the
exception of hormonal contraceptives, within the period
starting 14 days prior to first administration of the study
drug. Allergy to chicken eggs or influenza vaccine was an
exclusion criteria. Subjects with a body mass index
between 19 and 30 were enrolled
Study design
This was a single escalating dose study comprised of three
treatment groups. Eight subjects in Panel A received an
open label, single subcutaneous dose of AVI-014 at a dose
of 4 μg/kg. Subjects in Panel B were administered with
either a single subcutaneous dose of AVI-014 4 μg/kg (n =
8) or an equivalent dose of filgrastim (Neupogen, Amgen)
4 μg/kg (n = 8) in a double blinded fashion. Subjects in
Panel C were administered with either a single subcutane-
ous dose of AVI-014 8 μg/kg (n = 8) or an equivalent dose
of filgrastim 8 μg/kg (n = 8) in a double blinded fashion.
This was a first-in-human administration of AVI-014, and
no formal power calculation was performed. Prior to
unblinding, the computer-generated randomization
scheme was accessible only to the study statistician and to
the unblinded study staff member. Neither of these indi-
viduals assessed adverse events. All pharmacokinetic and
pharmacodynamic analysis was performed prior to
unblinding.
Each subject received a comprehensive medical history
and inquiry into concomitant medication use, complete
physical examination, clinical laboratory safety assess-
ments (hematology, blood chemistry, liver function tests,
and urinalysis), and ECG during screening. Females had a
negative serum pregnancy test during screening as well as
a negative urine pregnancy test on the first day of the study
prior to study drug administration. Subjects received a sin-
gle subcutaneous injection in the abdomen of study drug
followed by pharmacokinetic and pharmacodynamic
sampling. ECG examination was performed at screening,
within 1 hour prior to dosing, and at 6 hours and 21 days
post study drug administration. Injection sites were mon-
itored for signs of irritation or inflammation.
Pharmacokinetics
Blood for pharmacokinetics was drawn at baseline and
0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours after
drug administration. Blood samples were allowed to clot
and serum was collected and stored at <-20°C. Serum lev-
els of AVI-014 and control filgrastim were determined
using a hG-CSF specific ELISA kit (R&D Systems, Minne-BMC Clinical Pharmacology 2009, 9:2 http://www.biomedcentral.com/1472-6904/9/2
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apolis, MN). Concentration was calculated by interpola-
tion using a standard curve generated with either AVI-014
or filgrastim. The limit of quantification of the assay was
7.8 pg/ml.
Pharmacodynamics
Pharmacodynamic endpoints included absolute neu-
trophil count (ANC), total white blood cell (WBC) count
and total CD 34+ cell count. A complete blood count was
obtained predose and on days 2–9. Blood for flow cytom-
etry was collected predose and days 2–6. With the excep-
tion of the predose draw, which was collected at
approximately 20:00 on day -1, blood for pharmacody-
namic evaluation was collected at the dose time. CD 34+
counts were performed by the Thomas Jefferson Univer-
sity Hospital Clinical Laboratory. During flow cytometry
of subject samples, the gated area for CD 34 positive cells
was determined by visual inspection with an effort to
maintain consistency between samples. All flow cytome-
try and clinical laboratory personnel were blinded during
the conduct of the study.
Pharmacokinetic data analysis
Pharmacokinetic analysis was performed using WinNon-
Lin Enterprise version 5.1 (Pharsight Inc., Mountain View,
CA). A non-compartmental approach was employed. Area
under the curve (AUC) was determined using the linear/
log trapezoidal rule. Actual sample collection times were
used for the generation of pharmacokinetic parameters.
Individual time concentration plots were examined for
each subject. Appropriateness of time points to be used in
calculation of the elimination rate constant was verified
by visual examination of the terminal time points. In all
cases the terminal elimination was determined from the
24 to 72 hour time point. Estimation of an alpha half life
was performed using the time points of 8 to 24 hours.
Statistical methods
Pharmacokinetics
AUC's and Cmax values were natural log-transformed.
Means, standard deviations, min, max and medians were
calculated for each dose level and group (AVI-014 and fil-
grastim). Arithmetic means were be back-transformed (by
taking anti-logs) to obtain geometric means. The a priori
bounds that would define pharmacokinetic equivalence
of AVI-014 and filgrastim were a 90% confidence interval
of geometric mean ratio of area under the time concentra-
tion curve (AUC(0–72)) and of the maximal G-CSF con-
centration (Cmax) that lies between 0.8 and 1.25. A linear
mixed effects model was used to compare AVI-014 and fil-
grastim for the parameters of AUC(0–72) and Cmax. This
model had treatment as a fixed effect. Panel and session
nested within panel were also fixed effects. The variances
were calculated for each group, using subject as random
effects. Ratios (AVI-014/filgrastim) of geometric means
were calculated by back-transforming the difference of
least-squares mean, and a 90% confidence interval calcu-
lated for this ratio. Residuals were computed and exam-
ined for normality.
Pharmacodynamics
WBC, ANC and CD 34+ were analyzed as percentage
increase from the baseline, with determination of an area
under the % increase curve (AUC(0–9 day) for WBC and
ANC, and AUC(0–6 day) for CD34+), the maximal %
increase from baseline (Cmax). Units for AUC are %
increase-day; and for Cmax are % increase. The distance
between day 0 and day 2 was considered to be 1.5 days for
Table 1: Subject demographics by treatment allocation
Panel A Panel B Panel C
Category AVI-014 4 μg/kg AVI-014 4 μg/kg Filgrastim 4 μg/kg AVI-014 8 μg/kg Filgrastim 8 μg/kg
n 8 8888
Race n (%) White 4 (50.0) 2 (25.0) 3 (37.5) 3 (37.5) 1 (12.5)
Black 4 (50.0) 6 (75.0) 5 (62.5) 5 (62.5) 7 (87.5)
Gender n (%) Male 7 (87.5) 5 (62.5) 4 (50.0) 5 (62.5) 8 (100.0)
Female 1 (12.5) 3 (37.5) 4 (50.0) 3 (37.5) 0 (0.0)
Age (years) Mean (SD) 33.6 (7.8) 35.4 (6.6) 30.3 (5.1) 33.8 (5.7) 39.6 (7.3)
Weight (kg) Mean (SD) 78.3 (10.4) 81.2 (12.1) 79.4 (7.9) 76.3 (6.1) 90.6 (11.9)
Height (cm) Mean (SD) 177 (11) 175 (8) 170 (10) 173 (5) 181 (4)BMC Clinical Pharmacology 2009, 9:2 http://www.biomedcentral.com/1472-6904/9/2
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the purposes of determination of area under the curve.
Geometric mean ratios of AUC and Cmax were compared,
and the data were analyzed in the same fixed effects model
as for pharmacokinetics. The a priori bounds that defined
pharmacodynamic equivalence of AVI-014 and filgrastim
were a 90% confidence interval of geometric mean ratio of
area under the % increase curve (AUC) and of the maxi-
mal % increase from baseline (Cmax) that lay between 0.5
and 2.0.
Results
Subjects
The mean age of the subjects enrolled in the trial was 34.5
years (range 21–50). Twenty nine (73%) of the subjects
were male. Thirteen (32.5%) of the subjects were white
and 27 (67.5%) were black. The mean weight was 81 kg
(range 61–106). Demographics by treatment allocation
are presented in Table 1. All subjects who were allocated
to treatment received study drug (AVI-014 or filgrastim)
and all 40 subjects who enrolled completed the study.
Pharmacokinetics
A summary of PK parameters by treatment for all groups
is presented in Table 2. Graphical representation of con-
centration vs. time plots are presented in Figures 1, 2
(between treatments at the same dose level) and in Figure
3 (between doses for the same treatment). A summary of
geometric mean ratios comparing AVI-014 and filgrastim
at equal doses are presented in Tables 3 (4 μg/kg, Panel B
only) and Table 4 (8 μg/kg). At the 4 μg/kg dose level, AVI-
014 and filgrastim had similar AUC(0–72) values as evi-
denced by a point estimate of the geometric mean ratio of
1.00. However, the 90% confidence interval is outside the
a priori bioequivalence bounds of 0.8–1.25. The point
estimates for Cmax for the 4 μg/kg range, as well as
AUC(0–72) and Cmax for the 8 μg/kg dose show slightly
higher values for filgrastim. There was no formal hypoth-
esis testing examining other pharmacokinetic parameters,
but at equivalent mass doses, AVI-014 and filgrastim
appear generally comparable in terms of clearance, vol-
ume of distribution, terminal elimination half life, and
the estimated alpha half life generated by examining the
slope of the exponential decline between time points 8
and 24 hours. The geometric mean ratios between treat-
ments did not appreciably change when analysis was per-
formed using combined data from Panels A and B
compared to using only blinded administration in Panel
B. Comparisons presented here employ blinded adminis-
tration data (i.e., Panel B only).
Pharmacodynamics
Peak WBC and ANC occurred on day 2, with a return to
baseline values at approximately day 6. CD 34+ peak val-
AVI-014 at 4 μg/kg and 8 μg/kg (with standard error) Figure 3
AVI-014 at 4 μg/kg and 8 μg/kg (with standard error).
4 μg/kg Dose of AVI-014 and Filgrastim, (with standard  error) Figure 1
4 μg/kg Dose of AVI-014 and Filgrastim, (with stand-
ard error).
8 μg/kg Dose of AVI-014 and Filgrastim, (with standard  error) Figure 2
8 μg/kg Dose of AVI-014 and Filgrastim, (with stand-
ard error).BMC Clinical Pharmacology 2009, 9:2 http://www.biomedcentral.com/1472-6904/9/2
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ues occurred on day 3 for the 4 μg/kg groups and day 4 for
the 8 μg/kg groups. AVI-014 and filgrastim demonstrate
similarity in WBC, ANC, and CD 34+ response at equal
mass doses of drug. Geometric mean ratios of ANC, WBC
and CD 34+ cell counts between treatments are presented
in Tables 5, 6. Graphical representation of ANC is pre-
sented in Figures 4 and 5. Pharmacodynamic bioequiva-
lence for WBC and ANC between AVI-014 and filgrastim
was met, as 90% confidence intervals for the point esti-
mate of the geometric mean ratios of AUC and Cmax lay
within the a priori 0.5–2.0 bounds. The point estimates
for CD 34+ of the geometric mean ratios were close to
one, though the confidence intervals were high, reflecting
the large variance seen in the data. As with pharmacoki-
netics, the geometric mean ratios between treatments did
not appreciably change when analysis was performed
using combined data from Panels A and B compared to
using only blinded administration in Panel B.
Safety results
Adverse events
All subjects completed the trial. There were no serious
adverse events. A total of 47.5% of the enrolled subjects
experienced at least one adverse event. Of a total of 42
adverse events, thirty-four events were judged as possibly
related to study drug. The most common adverse events
were headache, myalgia, back pain, and bone pain. 50.0%
(12 of 24) of subjects treated with AVI-014 and 43.8% (7
of 16) of those treated with filgrastim had an adverse
event. Musculoskeletal complaints, which included bone
pain and muscle aches, occurred in 37.5% (9 of 24) sub-
jects receiving AVI-014 and 18.8% (3 of 16) subjects
receiving filgrastim. Headache occurred in 20.8% (5 of
24) subjects receiving AVI-014 and 18.8% (3 of 16) of
subjects receiving filgrastim. A sensation of neck fullness
was noted in two subjects on the day of drug administra-
tion. One subject noted headache, dizziness, chest dis-
comfort, and nausea approximately 45 minutes after
receiving AVI-014 4 μg/kg. This resolved and approxi-
mately eight hours later this subject noted a sensation of
neck fullness. The event in this subject occurred 30 min-
utes after his roommate, who received filgrastim 4 μg/kg,
noted neck fullness. Both episodes were self-limited, not
associated with other signs of hypersensitivity, and con-
sidered possibly related to study drug. Injection site pain
occurred in one subject receiving AVI-014.
Immunogenicity
For all subjects, serum neutralizing antibodies and bind-
ing antibodies were assessed by serum-mediated inhibi-
Table 3: Pharmacokinetic geometric mean ratios of AVI-014/filgrastim at 4 μg/kg
PK parameter Dose mcg/kg Geo Mean AVI-014 (n = 16) Geo Mean Filgrastin (n = 8) P value Geo Mean Ratio (90% CI)
AUC(0–72) 4 169.545 170,259 0.9766 1.00 (0.76, 1.31)
Cmax 4 18,830 21,855 0.2952 0.86 (0.66, 1.13)
Table 2: Pharmacokinetic parameters by treatment and dose level
Treatment Dose N Cmax AUC(0–72) AUC(0-∞) Clearance Terminal 
elimination 
half life
Estimated 
Alpha half 
life
Volume of 
distribution
Volume of 
distribution
Tmax*
mcg/kg pg/mL hr*pg/mL hr*pg/mL mL/min hr hr L L/kg hr
AVI-014 4 16 16,944 
(5,804)
138,993 
(48,262)
139,818 
(48,332)
43 (18) 15.1 (3.6) 3.4 (0.5) 58 (33) 0.73 (0.37) 4.5
Filgrastim 4 8 22,595 
(6,076)
175,323 
(50,665)
176,145 
(51,004)
32 (8) 14.7 (3.9) 2.8 (0.6) 42 (19) 0.54 (0.27) 5
AVI-014 8 8 31,460 
(7,927)
312,569 
(81,029)
313,525 
(81,043)
35 (11) 11.0 (2.2) 3.7 (0.3) 35 (18) 0.45 (0.23) 5
Filgrastim 8 8 41,442 
(9,986)
347,053 
(70,749)
347,489 
(70,698)
36 (10) 9.8 (2.3) 3.1 (0.5) 31 (15) 0.35 (0.14) 6
All values are means with (SD), except in the case of Tmax.
* = medianBMC Clinical Pharmacology 2009, 9:2 http://www.biomedcentral.com/1472-6904/9/2
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tion of in vitro cell proliferation assays and by ELISA
detection/quantification of hα-G-CSF antibodies using
goat  α-human Ig-peroxidase conjugate (ZeptoMetrix).
Blood sampling for immunogenicity testing was per-
formed at pre-dose and on day 21 time points. No hG-CSF
neutralizing antibodies were detected in pre-dose or day
21 samples from any subject. One patient who had
received AVI-014 at 8 μg/ml showed low levels (<3 ng/ml)
of anti-hG-CSF antibodies in both pre-dose and day 21
samples, with equivalent levels at both time points. Low
levels of naturally occurring anti-G-CSF antibodies in nor-
mal subjects have previously been reported to be relatively
common (11% of subjects) [6]. Thus, no treatment-
related immunogenicity was observed.
Discussion
This study describes the first human administration of
AVI-014, an avian-derived, human, glycosylated G-CSF.
AVI-014 was well tolerated, with a side effect profile of
myalgia and bone pain that was comparable to that seen
with a similar dose of filgrastim. The product insert for fil-
grastim notes a ~3.5 hour elimination half life [7,8],
which corresponds to the estimated alpha half life noted
in the present study. Filgrastim has been previously
described in a two compartment model with dose-
dependent, saturable elimination [9]. We employed a sen-
sitive G-CSF assay with a limit of quantification of 7.8 pg/
ml, which is an order of magnitude more sensitive than
those employed by Wang in 2001 [9] or Borleffs in 1998
[8]. The capture of data points closer to the limit of quan-
tification of the assay allowed for the detection of the ter-
minal elimination phase at the doses administered in the
trial. This also accounts for differing values of volume of
distribution compared to the product insert and earlier
published information. Other pharmacokinetic parame-
ters observed for filgrastim are similar to those previously
published [7,10].
The comparative extent of G-CSF exposure, as determined
by AVI-014 and filgrastim AUC(0–72) values, appeared
comparable at 4 μg/kg and 8 μg/kg dose. However, the
90% confidence interval of the geometric mean ratio is
outside a priori bioequivalence bounds of 0.8–1.25. It
should be noted that this study employed a parallel and
not crossover design and thus does not constitute a formal
exploration of bioequivalence. A parallel design was cho-
sen because of unknown immunogenicity of AVI-014 in
this first-in-human clinical trial. There was no evidence of
immunogenicity noted in this trial, which is consistent
with the experience of an egg white-derived interferon
alpha-2b [11]. The use of a parallel and not crossover
design is not expected to bias the analysis toward
bioequivalence. Indeed, intra-subject variability intro-
duced by the parallel design employed in the present
study would likely make demonstration of bioequiva-
lence more difficult.
The response of each product in terms of WBC, neutrophil
response and CD 34+ was similar between treatments.
8 μg/kg Dose of AVI-014 and Filgrastim Absolute Neutrophil  Count Response, (with standard error) Figure 5
8 μg/kg Dose of AVI-014 and Filgrastim Absolute 
Neutrophil Count Response, (with standard error).
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Table 4: Pharmacokinetic Geometric Mean ratios of AVI-014/Filgrastim at 8 μg/kg
PK parameter Dose μg/kg Geometric Mean AVI-014 
(n = 8)
Geometric Mean Filgrastin 
(n = 8)
P value Geometric Mean Ratio 
(90% CI)
AUC(0–72) 8 301,979 340,837 0.3669 0.89 (0.69, 1.14)
Cmax 8 30,467 40,325 0.0550 0.76 (0.58, 0.98)
4 μg/kg Dose of AVI-014 and Filgrastim Absolute Neutrophil  Count Response, (with standard error) Figure 4
4 μg/kg Dose of AVI-014 and Filgrastim Absolute 
Neutrophil Count Response, (with standard error).BMC Clinical Pharmacology 2009, 9:2 http://www.biomedcentral.com/1472-6904/9/2
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This is consistent with previous observations which dem-
onstrated a close linkage between the serum concentra-
tion of recombinant G-CSF and neutrophil response [12],
as well as other observations suggesting similarity of
response to glycosylated and non-glycosylated recom-
binant G-CSF preparations [13]. Pharmacodynamic
bioequivalence for WBC and ANC between AVI-014 and
filgrastim was met, as 90% confidence intervals for the
geometric mean ratios of AUC and Cmax lay within the a
priori 0.5–2.0 bounds. The geometric mean ratios for CD
34+ were close to 1, though the confidence intervals were
high possibly due to the large variance seen in the data.
Conclusion
In conclusion, AVI-014 was well tolerated in healthy sub-
jects with no evidence of immunogenicity. AVI-014 has a
pharmacokinetic profile in healthy volunteers that is com-
parable to that of filgrastim and generates a pharmacody-
namic response in terms of neutrophil mobilization that
is equivalent to that of filgrastim. The present report sup-
ports further investigations of AVI-014 in patient popula-
tions.
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